Last Updated: September 24, 2026

Details for Patent: 8,329,692


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,329,692 protect, and when does it expire?

Patent 8,329,692 protects TEPMETKO and is included in one NDA.

This patent has eighty patent family members in thirty-seven countries.

Summary for Patent: 8,329,692
Title:Pyrimidinyl pyridazinone derivatives
Abstract:Compounds selected from the group according to Claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.
Inventor(s):Oliver Schadt, Dieter Dorsch, Frank Stieber, Andree Blaukat
Assignee: Merck Patent GmbH
Application Number:US12/668,491
Patent Claim Types:
see list of patent claims
Composition; Compound; Device;

Drugs Protected by US Patent 8,329,692

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Emd Serono Inc TEPMETKO tepotinib hydrochloride TABLET;ORAL 214096-001 Feb 3, 2021 RX Yes Yes 8,329,692 ⤷  Start Trial Y Y ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,329,692

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2007 032 507Jul 12, 2007
PCT/EP2008/003473Apr 29, 2008
PCT Information
PCT FiledJuly 04, 2008PCT Application Number:PCT/EP2008/005508
PCT Publication Date:January 15, 2009PCT Publication Number: WO2009/007074

International Family Members for US Patent 8,329,692

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2164843 ⤷  Start Trial C02164843/01 Switzerland ⤷  Start Trial
European Patent Office 2164843 ⤷  Start Trial 301176 Netherlands ⤷  Start Trial
European Patent Office 2164843 ⤷  Start Trial PA2022009 Lithuania ⤷  Start Trial
European Patent Office 2164843 ⤷  Start Trial 2022C/519 Belgium ⤷  Start Trial
European Patent Office 2164843 ⤷  Start Trial LUC00264 Luxembourg ⤷  Start Trial
European Patent Office 2164843 ⤷  Start Trial CA 2022 00021 Denmark ⤷  Start Trial
European Patent Office 2164843 ⤷  Start Trial 122022000047 Germany ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.